Table S4. Summary table of quality assessment ratings of RCTs of aspirin for the primary prevention of CVD (n = 3)

*Based on the Cochrane Risk of Bias tool* [22]

|  |  |  |  |
| --- | --- | --- | --- |
| **Question** | **Nelson 2008 [53]** | **Dorresteijin 2011 [54]** | **Fowkes 2010 [10]** |
| 1. Adequate sequence generation | Yes | Yes | Yes |
| 2. Adequate allocation concealment | Unclear | Yes | Yes |
| 3. Blinding (especially outcome assessment) | Yes (“*double blind*”) | Yes | Yes |
| 4. Incomplete outcome data addressed | Yes (*reported 12 month follow up attendance)* | Yes | Yes |
| 5. Free of selective reporting | Yes | Yes | Yes |
| 6. Free of other potential bias1 | Yes | Yes | Yes |

1 e.g. similarity at baseline, power assessment, conflict of interest